Tagged with IOT

LatAm Roberto Alvarenga, VP at Biotronik’s Latin American operations, reflects on the company’s six decades of innovation and LatAm’s emergence as the firm’s fastest-growing region. He outlines a strategy focused on continuous innovation, digital health integration, and demonstrating health-economic value, while navigating the complex dynamics of public and private healthcare systems…

Taiwan After more than two decades in Silicon Valley, Dr Jeng Her returned to Taiwan with a bold ambition: to help transform its emerging biotech sector into a globally recognised force in antibody innovation. As Founder and CEO of AP Biosciences, he has positioned the company at the forefront of bispecific…

Taiwan Dr Wen-Liang Huang, General Manager of Ever Supreme Biotechnology, brings over 40 years of clinical cardiology experience to biopharmaceutical leadership. Recruited by the company’s founder, his medical background informs the translation of cell therapy innovations into meaningful patient treatments. Under his guidance, Ever Supreme has become Taiwan’s pioneering cell therapy…

Taiwan Dr Chiu-Heng Chen (John), CEO of LaunXP, brings a unique perspective to oncology drug development shaped by his personal experience with cancer during his PhD in the UK. Holding advanced degrees from British and Taiwanese institutions in tumour oncology, he founded LaunXP in 2015 to bridge academia and clinical practice,…

France As CEO of Transgene, Alessandro Riva is steering the French biotech into a new era of cancer immunotherapy. Building on more than four decades of scientific excellence, Transgene is advancing a pioneering platform of individualised neoantigen therapeutic vaccines (INTVs) designed to re-educate the immune system to target solid tumours. With…

France Under Laurence Rodriguez’s leadership, GenSight Biologics is charting a bold path forward after a period of reset, advancing groundbreaking gene therapies for rare ophthalmic and mitochondrial diseases. She reflects on rebuilding the organisation, preparing a pivotal Phase III study for the gene therapy GS010/LUMEVOQ, and shaping the future of optogenetic…

France Born from a serendipitous scientific discovery in Montpellier, Abivax has evolved into one of France’s most promising global biotechs. Led by CEO Marc de Garidel, the company is harnessing its pioneering miR-124-based therapy, obefazimod, to redefine treatment possibilities in inflammatory bowel disease through an entirely new, immune-balancing mechanism of action.…

France Genopole stands as one of France’s leading bioclusters, seamlessly integrating world-class research, entrepreneurship, and industrial engagement to support over 80 companies across health and the bioeconomy. Under Gilles Trystram’s leadership, the cluster nurtures innovation from start-up creation to scaling, leveraging strategic partnerships with institutions like Université Paris-Saclay and specialised platforms…

China In just four years, Shanghai-based Argo Biopharma has gone from a start-up to one of China’s most internationally recognised RNA innovators and has signed two major licensing deals with Novartis worth up to USD 6 billion. These Novartis deals could come to be one of the largest ever tie-ups between…

USA As the world’s largest stock exchange, the New York Stock Exchange (NYSE) plays a pivotal role in shaping access to capital for healthcare and life sciences companies. Johanna Grossman, PhD, who leads this sector for the NYSE, reflects on her career path, the exchange’s growing footprint in biotech, and the…

USA Tim Scott, President and CEO of Biocom California, leads the state’s largest and most influential life sciences association at a pivotal moment for the industry. With more than 1,800 members across biotech, pharma, medtech, diagnostics, and research institutions, Biocom California represents the full breadth of the ecosystem. In this interview,…

USA In 2025, just 318 US biotech deals closed in Q2 – the lowest in a decade – even as mega-rounds propped up total investment volumes. For a sector that was booming during the pandemic era, the contrast could not be starker. Leaders from trade organisations and innovation accelerators agree on…